Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis.
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at the Ohio State University Comprehensive Cancer Center is using artificial intelligence to devise new ways of predicting which patients will develop an aggressive and difficult-to-detect form of breast cancer called lobular cancer, which represents one in every 10 breast cancers diagnosed in the United States.
Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies as we age. In the largest study to date, they have used the tool to provide insights into the earliest steps of cancer development and the role of mutations in healthy tissue.
Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.
Cell and gene therapies are steadily becoming more available to patients, but are still facing systemic hurdles slowing widespread adoption, according to the second annual 2025 “Cell and Gene Therapy Report: Advancing the Future of Medicine,” published by InspiroGene by McKesson. The report draws on new insights from research with physicians and payers, an updated... […]
The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial—a large-scale, phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.
When cells divide, DNA must be copied from one cell to the next—a process called replication.
Wistar Institute researchers have overturned three decades of scientific thinking about p53, the most important tumor suppressor protein in cancer research.
UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting cancer-associated fibroblasts that appear to support the survival and growth of malignant tumors.
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy went more than twice as long without their disease worsening compared with those who received SBRT alone, according to new clinical trial results from UCLA Health Jonsson Comprehensive Cancer Center researchers.
